All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Hims & Hers to sell Grail's Galleri multi-cancer blood test via digital platform
Commercialization partnership, oncology, diagnostics, digital health - Read more

OXB, Bristol Myers Squibb expand partnership for commercial lentiviral vector manufacturing for CAR-T therapies
Manufacturing agreement, cell therapy, gene therapy, lentiviral vectors - Read more

Evogene, Shanghai Lishan Biopharmaceuticals license BMC128 microbiome therapeutic for renal and lung cancer
Licensing deal, oncology, microbiome therapeutics, milestone payments - Read more

Saya Biologics, Kashiv BioSciences partner on biosimilar supportive oncology therapy for Mexico and CAC region
Commercialization partnership, oncology, biosimilar, manufacturing agreement, regulatory - Read more

THE GOOD
Clinical Trials

Eli Lilly's Zepbound (tirzepatide) plus Taltz combo meets Ph3b endpoints in psoriatic arthritis
Small molecule, autoimmune, GLP-1 agonist, psoriatic arthritis, combination therapy, obesity comorbidity - Read more

UCB's Bimzelx (bimekizumab) shows three-year inflammatory lesion resolution in Ph3 hidradenitis suppurativa trials
Antibody, autoimmune, monoclonal antibody, hidradenitis suppurativa, IL-17 inhibitor, inflammatory lesions - Read more

Pharmazz presents positive Ph4 interim results for sovateltide (Tycamzzi) targeting endothelin-B receptor in acute cerebral ischemic stroke
Small molecule, neurological, endothelin receptor agonist, acute ischemic stroke - Read more

Amgen's daxdilimab hits Ph2 primary endpoint for discoid lupus erythematosus targeting immunoglobulin-like transcript 7
Monoclonal antibody, autoimmune, discoid lupus erythematosus, gastric cancer, immunoglobulin-like transcript 7 - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Earnings & Finances

Novartis CEO projects 2026 growth despite massive $4B patent cliff-caused revenue hole
Small molecule, oncology, financial, patent cliff, revenue impact - Read more

Eli Lilly projects 25% sales surge to $80-83B in 2026 despite pricing headwinds
Small molecule, diabetes, financial, competitive - Read more

Eli Lilly's Q4 revenue jumps 43% to $19.3B driven by Mounjaro and Zepbound sales growth
Small molecule, diabetes, financial, revenue impact - Read more

AbbVie's immunology portfolio generates $30B in sales while executives emphasize diversification into oncology, neuroscience areas
Monoclonal antibody, autoimmune, strategic, financial - Read more

Amgen reports Q4 revenue of $9.9B, beating estimates while touting obesity pipeline potential
Monoclonal antibody, cardiovascular, financial, strategic - Read more

GSK shares rise 5% as new CEO Miels reports strong financials in first results
Vaccines, infectious disease, financial, strategic - Read more

THE GOOD
Fundraises

Salspera files $50M IPO, live biopharmaceuticals for immuno-oncology cancer treatment
Immuno-oncology, live biotherapeutics, clinical-stage, pancreatic cancer - Read more

Third Arc Bio raises $52M Series A extension for oncology/immunology antibodies
Oncology, antibody, immunology & inflammation, multispecific antibodies, clinical-stage - Read more

THE GOOD
Mergers & Acquisitions

Nanologica acquires Ardena's Syntagon API facility for $961K, adding 45 employees in Sweden expansion
Active pharmaceutical ingredients, strategic, major transaction, operational - Read more

Medtronic to acquire Israeli devicemaker CathWorks for up to $585M for coronary artery disease technology
Medical device, cardiovascular, strategic, major transaction - Read more

PrimeGen merges with DT Cloud Star SPAC for $69M Nasdaq listing to advance stem cell therapies
Stem cell therapy, liver disease, strategic, major transaction - Read more

THE GOOD
Politics & Policy

President Trump signs spending bill reauthorizing rare pediatric disease vouchers, ending uncertainty for rare disease developers
Rare disease, pediatric, regulatory, financial incentive, strategic - Read more

THE GOOD
Strategic Plans

GSK's new CEO targets $2B-$4B deals following $2.2B Rapt Therapeutics acquisition for ozureprubart
Monoclonal antibody, allergies, strategic, major transaction - Read more

GSK CEO Luke Miels outlines product-centric vision with Exdensur and Blenrep launches driving growth strategy
Monoclonal antibody, respiratory disease, strategic, operational - Read more

GSK rejects GLP-1 market entry, focuses on obesity complications like fatty liver disease instead
Protein therapeutic, metabolic disease, strategic, major transaction - Read more

Novartis CEO confirms continued M&A strategy targeting early pipeline and near-launch assets after major 2025 acquisitions
Molecular glue degrader, oncology, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Eli Lilly discontinues LY3884963 gene therapy for frontotemporal dementia after Ph2 efficacy concerns
Gene therapy, neurological, frontotemporal dementia, antibody, autoimmune, anti-CD19 - Read more

THE BAD
Earnings & Finances

Novartis faces largest patent expiry in history, wiping $4B sales in 2026 despite overall growth
Small molecule, cardiovascular, patent expiry, revenue impact, competitive, strategic - Read more

Novo Nordisk stock drops 17% after CEO dismisses crisis concerns amid declining 2026 guidance forecast
GLP-1 agonist, metabolic disease, competitive, revenue impact - Read more

THE BAD
Regulatory

Democratic Rep criticizes FDA's Commissioner's Priority Voucher program for lacking transparency and congressional approval
Gene therapy, diabetes, regulatory, operational, strategic - Read more

Amgen refuses FDA request to withdraw rare disease drug Tavneos over clinical data concerns
Small molecule, rare disease, regulatory, strategic - Read more

THE BAD
Strategic Plans

Novartis discontinues 6 early-stage programs while adding 2 new phase 1 cancer candidates to pipeline
Small molecule, oncology, strategic, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here